RxDoctor Payments Data

John Flores, MD

Internal Medicine · Little Elm, TXNPI 1568449593

Payments from drug & device makers

$110,591in general payments, 2019–2025

Across 435 payments — averaging $254.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$104K
  • AstraZeneca$2K
  • Abbott$1K
  • Lilly USA, LLC$669
  • Johnson & Johnson$398
  • AbbVie$345
  • plus $2K from 23 others

What the payments were for

  • Consulting fees$30,78228%
  • Speaking & faculty fees$55,86351%
  • Travel & lodging$12,22711%
  • Food & beverage$11,39010%
  • Education$3280%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$110,591 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$31,632
Medicare patients
46
Services billed
382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$77,214
MounjaroTirzepatide14$21,387
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$20,900
JanuviaSitagliptin Phosphate13$14,154
EliquisApixaban12$10,680
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen114$2,564
Fentanyl24$2,190
Ezetimibe50$1,372
Fenofibrate25$1,224
Oxycodone Hcl52$1,224
Atorvastatin Calcium162$1,172
Rosuvastatin Calcium48$876
Tamsulosin Hcl31$772
Metoprolol Succinate54$771
Omeprazole40$719

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$103,578$77,21464 claims
Lilly USA, LLCMounjaro$669$21,38714 claims
MerckJanuvia$161$14,15413 claims
PfizerEliquis$41$10,68012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Little Elm

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →